Martin Pavane

Martin Pavane

Cozen O'Connor

Contact  |  View Bio  |  RSS

Latest Publications

Share:

Pre-Emption of State-Law Design-Defect Claim Against Generic Drug Company

On June 24, 2013, in a 5-4 decision, the U.S. Supreme Court in Mutual Pharmaceutical Co., Inc. v. Bartlett held that state-law design-defect claims based on the inadequacy of a generic drug’s labeled warnings are pre-empted...more

7/4/2013 - Design Defects FDA Generic Drugs Mutual Pharmaceuticals v Bartlett Preemption Prescription Drugs SCOTUS Warning Labels

Supreme Court: Reverse Payment Settlements Subject to Antitrust Scrutiny

On June 17, 2013, the U.S. Supreme Court handed down a decision that addressed a “reverse payment” settlement agreement between a brand-name pharmaceutical company (plaintiff patent holder) and multiple generic drug companies...more

6/26/2013 - ANDA Antitrust Litigation FTC FTC v Actavis Generic Drugs Hatch-Waxman Patent Infringement Pharmaceutical Reverse Payment Settlement Agreements SCOTUS

2 Results
|
View per page
Page: of 1